Latest news with #SMSPharmaceuticals


Business Upturn
7 days ago
- Business
- Business Upturn
SMS Pharmaceuticals share jump 6% after its Hyderabad facility clears USFDA inspection with zero observations
By Aman Shukla Published on June 26, 2025, 09:24 IST Shares of SMS Pharmaceuticals surged 6% in early trade after the company announced the successful completion of a USFDA inspection at its Central Laboratory Analytical Services in Gagillapur, Hyderabad. As of 9:23 AM, the shares were trading 5.77% higher at Rs 252.90. The inspection, conducted between June 23 and June 25, 2025, concluded with zero Form 483 observations — a clear indicator of full compliance with USFDA norms. This is the second successful USFDA audit at the lab, underlining the company's robust quality assurance systems and regulatory preparedness. The Central Lab operates as an independent analytical testing facility, serving as a key quality control hub for the company. The clean report from the USFDA reinforces SMS Pharma's strong adherence to Current Good Manufacturing Practices (CGMP) and Good Laboratory Practices (GLP) across its operations. This development boosts investor confidence, as regulatory compliance plays a crucial role in pharmaceutical exports to the US — one of SMS Pharma's key markets. It also strengthens the company's reputation as a trusted global pharmaceutical player, with a sharp focus on quality, safety, and transparency. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Standard
7 days ago
- Business
- Business Standard
SMS Pharma's Hyderabad facility clears USFDA inspection with zero observations
SMS Pharmaceuticals announced that its Central Laboratory Analytical Services, located at, Gagillapur, Telangana, has successfully cleared the recent inspection by the US Food and Drug inspection (USFDA) with zero observations. The inspection was conducted from 23rd June 2025 to 25th June 2025, concluded with zero Form-483 observations. The company said that the Central Laboratory Analytical Services is its independent testing laboratory, and this was the second successful USFDA inspection for the facility. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag. The companys consolidated net profit jumped 17.6% to Rs 20.32 crore on 1% increase in net sales to Rs 248.20 crore in Q4 FY25 over Q4 FY24. The counter added 2.31% to end at Rs 239.05 on the BSE.


Business Upturn
25-06-2025
- Business
- Business Upturn
SMS Pharmaceuticals clears second USFDA inspection at Hyderabad lab with zero observations
By Aman Shukla Published on June 25, 2025, 16:19 IST SMS Pharmaceuticals has recently informed exchanges that the company successfully completed its second inspection by the United States Food and Drug Administration (USFDA) at its Central Laboratory Analytical Services in Gagillapur, Hyderabad. The inspection, held from June 23 to June 25, 2025, concluded with zero Form 483 observations, reflecting the company's strong focus on quality and compliance. This Central Lab is an independent analytical testing facility, and the clean inspection outcome reaffirms SMS Pharma's commitment to CGMP and GLP standards across all its units. The company continues to maintain world-class quality practices, ensuring trust and reliability in every aspect of its operations. In the meantime, SMS Pharmaceuticals shares closed today at ₹239.00, after opening at ₹234.25. The stock touched an intraday high of ₹239.90 and a low of ₹234.25 during the session. The company's 52-week high stands at ₹398.00, while the 52-week low is ₹176.05. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Standard
02-05-2025
- Business
- Business Standard
SMS Pharmaceuticals' Unit VII receives WHO Geneva prequalification
SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva. The company added, "This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs." Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated: The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness."